Halozyme Therapeutics, Inc. (HALO)

NMS – Real Time Price. Currency in USD

101.46

-1.16 (-1.13%)

Market open: Aug 12, 2026, 2:26 PM EDT

104.19

+1.57 (1.53%)

Previous after-hours: Aug 11, 2026, 7:36 PM EDT

07.08.2026

Halozyme's Q2 Earnings Beat Estimates, 2026 Outlook Raised, Stock Up

HALO's Q2 earnings and revenues surpass estimates, fueled by higher royalties and product sales. The company raises its 2026 outlook.

07.08.2026

Halozyme Therapeutics Q2 Earnings Call Highlights

Halozyme Therapeutics NASDAQ: HALO reported record second-quarter revenue and raised its full-year outlook, citing growth in royalty income from its ENHANZE drug-delivery platform, contributions from newer product launches and revenue from newly signed collaboration agreements.

06.08.2026

Halozyme Therapeutics, Inc. (HALO) Q2 2026 Earnings Call Transcript

06.08.2026

Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics

Although the revenue and EPS for Halozyme Therapeutics (HALO) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

06.08.2026

Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates

Halozyme Therapeutics (HALO) came out with quarterly earnings of $2.28 per share, beating the Zacks Consensus Estimate of $1.82 per share. This compares to earnings of $1.54 per share a year ago.

06.08.2026

HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE

Total Revenue Increased 48% YOY to $481 million Royalty Revenue Increased 50% YOY to $308 million Raises 2026 Financial Guidance Ranges: Total Revenue of $1.835 - $1.910 billion, YOY Growth of 31% - 37% Royalty Revenue of $1.220 - $1.245 billion, YOY Growth of 41% - 43% Adjusted EBITDA of $1.225 - $1.280 billion, YOY Growth of 86% - 95% 1 Non-GAAP Diluted EPS of $8.65 - $9.00, YOY Growth of 108% - 117% 1 Signed Five New ENHANZE ® and Hypercon ™ Collaboration Agreements YTD 2026, Exceeding Goal of Three for Full Year 2026 SAN DIEGO, Aug. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the second quarter ended June 30, 2026, and provided an update on its recent corporate activities. "We delivered another quarter of strong performance, with multiple proof points demonstrating the attractive features of ENHANZE as a compounding platform engine: repeatability of success, scalability, diversification and durability of revenues," said Dr. Helen Torley, President and Chief Executive Officer.

Videos

No Data

There is no data to display

Upgrades / Downgrades

Ticker	Brokerage Firm	Ratings Change	Price Target	Date
HALO	Leerink Partners	Outperform	undefined >> $110	August 7th 2026

Press releases

06.08.2026

Halozyme Therapeutics, Inc. (HALO)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Halozyme Therapeutics, Inc. (HALO)

Halozyme's Q2 Earnings Beat Estimates, 2026 Outlook Raised, Stock Up

Halozyme Therapeutics Q2 Earnings Call Highlights

Halozyme Therapeutics, Inc. (HALO) Q2 2026 Earnings Call Transcript

Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics

Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates

HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE

Videos

No Data

Upgrades / Downgrades

Press releases

HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE

Halozyme's Q2 Earnings Beat Estimates, 2026 Outlook Raised, Stock Up

Halozyme Therapeutics Q2 Earnings Call Highlights

Halozyme Therapeutics, Inc. (HALO) Q2 2026 Earnings Call Transcript

Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics

Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates

HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE

Videos

No Data

Upgrades / Downgrades

Press releases

HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE

Search stocks

Halozyme Therapeutics, Inc. (HALO)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Halozyme Therapeutics, Inc. (HALO)

Halozyme's Q2 Earnings Beat Estimates, 2026 Outlook Raised, Stock Up

Halozyme Therapeutics Q2 Earnings Call Highlights

Halozyme Therapeutics, Inc. (HALO) Q2 2026 Earnings Call Transcript

Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics

Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates

HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE

Videos

No Data

Upgrades / Downgrades

Press releases

HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE

Halozyme's Q2 Earnings Beat Estimates, 2026 Outlook Raised, Stock Up

Halozyme Therapeutics Q2 Earnings Call Highlights

Halozyme Therapeutics, Inc. (HALO) Q2 2026 Earnings Call Transcript

Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics

Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates

HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE

Videos

No Data

Upgrades / Downgrades

Press releases

HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE